Skip to content

Company
Pipeline
For Investors
Contact

Company
Pipeline
For Investors
Contact

Press Releases

Choose Year
Search Press Releases

Found 267 Results

April 24, 2025

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

April 14, 2025

Relmada Therapeutics To Present NDV-01 Data at AUA2025

April 14, 2025

UPDATE — Relmada Therapeutics To Present NDV-01 Data at AUA2025

March 27, 2025

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

March 26, 2025

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

March 25, 2025

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

February 6, 2025

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB

December 9, 2024

Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

December 4, 2024

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance

November 19, 2024

Relmada Therapeutics to Present at Jefferies London Healthcare Conference

«...2 345 6 7...»

IR Contact

Brian Ritchie
LifeSci Advisors, LLC

+1 (212) 915-2578
britchie@lifesciadvisors.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy^*

Unsubscribe

Loading...

Company

Pipeline
Overview
NDV-01
Speranolone

For Investors
Summary
News
Events
SEC Filings
Corporate Governance
Stock Information

Contact

info@relmada.com

+1 (786) 629-1376

©2026 Relmada Therapeutics, Inc.

Privacy Policy
Terms of Use

Scroll to Top